Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese.

BACKGROUND Cytochrome P450-dependent monooxygenase 2D6 (CYP2D6) activity can be estimated by investigating the metabolism of model drugs or by genotyping the most common CYP2D6 alleles. For Caucasians, the CYP2D6 allele frequencies are well investigated, and single-step assays are available for genotyping, whereas allele analysis in mainland Chinese is limited. METHODS Two tetra-primer assays and one allele-specific amplification assay were developed to easily genotype the CYP2D6 alleles *8, *10, and *14 previously detected in Asians. Applying these assays in combination with established single-tube assays, we analyzed 223 DNA samples from Chinese volunteers for the CYP2D6 alleles *3, *4, *5, *6, *8, *10, and *14 and for duplication of CYP2D6. RESULTS Six different alleles were detected in mainland Chinese. The most frequent mutant allele was the intermediate metabolizer allele, CYP2D6*10, with a prevalence of 51.3%, followed by the poor metabolizer alleles CYP2D6*5 (7.2%) and a novel variant of CYP2D6*14. This novel *14B allele (2.0%) differs from the *14 allele by the absence of the C188T substitution and by the additional G1749C substitution. Furthermore, six duplication alleles of CYP2D6 were detected, including one duplication of the *10 allele (*10X2). CONCLUSIONS The CYP2D6 allele frequencies in mainland Chinese shows some genetic diversity compared with Chinese from other regions: a novel *14B allele, a slightly higher frequency of the *5 allele, and a slightly lower frequency of the *10 allele than in most other Chinese populations.

[1]  J. Weide,et al.  Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. , 1998, Clinical chemistry.

[2]  M. Ingelman-Sundberg,et al.  Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. , 1995, The Journal of pharmacology and experimental therapeutics.

[3]  F. Green,et al.  Allele specific amplification by tetra-primer PCR. , 1992, Nucleic acids research.

[4]  E. Skjelbo,et al.  Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. , 1999, British journal of clinical pharmacology.

[5]  Y. Wing,et al.  Occurrence of CYP2D6 gene duplication in Hong Kong Chinese. , 2000, Clinical chemistry.

[6]  L. Bertilsson,et al.  Pharmacokinetics of nortriptyline and its 10‐hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes , 1998, Clinical pharmacology and therapeutics.

[7]  A. Daly,et al.  Molecular basis of polymorphic drug metabolism , 1995, Journal of Molecular Medicine.

[8]  M. Ingelman-Sundberg,et al.  Nomenclature for human CYP2D6 alleles. , 1996, Pharmacogenetics.

[9]  J. Idle,et al.  The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. , 1994, Pharmacogenetics.

[10]  M. Ingelman-Sundberg,et al.  Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. , 1998, Pharmacogenetics.

[11]  R. Prough,et al.  Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. , 1997, Clinical chemistry.

[12]  J. Lafitte,et al.  Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. , 1997, Pharmacogenetics.

[13]  A. Molven,et al.  Ultrarapid metabolizers of debrisoquine: Characterization and PCR‐based detection of alleles with duplication of the CYP2D6 gene , 1996, FEBS letters.

[14]  Edmund Lee,et al.  OXIDATION PHENOTYPING IN CHINESE AND MALAY POPULATIONS , 1988, Clinical and experimental pharmacology & physiology.

[15]  U. Gundert-Remy,et al.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations , 2004, European Journal of Clinical Pharmacology.

[16]  M. Hersberger,et al.  Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. , 2000, Clinical chemistry.

[17]  M. Lai,et al.  Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes , 1999, Clinical pharmacology and therapeutics.

[18]  M. Subrahmanyam.  Storage of skin grafts in honey , 1993, The Lancet.

[19]  L. Bertilsson,et al.  Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. , 1995, Pharmacogenetics.

[20]  A. Molven,et al.  Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? , 2001, Pharmacogenetics.

[21]  L. Bertilsson,et al.  Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.

[22]  M. Lai,et al.  Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6 , 1993, Clinical pharmacology and therapeutics.

[23]  E. Lee,et al.  Frequency of human CYP2D6 mutant alleles in a normal Chinese population. , 1994, British journal of clinical pharmacology.

[24]  M Schwab,et al.  Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. , 2001, Pharmacogenetics.

[25]  M. Ingelman-Sundberg,et al.  PCR-based genotyping for duplicated and deleted CYP2D6 genes. , 1996, Pharmacogenetics.

[26]  H K Kroemer,et al.  "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. , 1995, Life sciences.

[27]  M. Ingelman-Sundberg,et al.  Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. , 1994, Molecular pharmacology.

[28]  M. Ingelman-Sundberg,et al.  Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine , 1993, The Lancet.

[29]  M. Lai,et al.  G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[30]  R. T. Coutts,et al.  Polymorphic Cytochromes P450 and Drugs Used in Psychiatry , 1999, Cellular and Molecular Neurobiology.

[31]  U. Meyer,et al.  Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. , 1992, Genomics.

[32]  J. Brockmöller,et al.  Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. , 1997, American journal of human genetics.

[33]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M Ingelman-Sundberg,et al.  Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. , 1996, The Journal of pharmacology and experimental therapeutics.

[35]  R. Tyndale,et al.  Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. , 2001, Pharmacogenetics.

[36]  M Ingelman-Sundberg,et al.  Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. , 1997, Pharmacogenetics.

[37]  J. Benítez,et al.  Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population , 1995, Clinical pharmacology and therapeutics.

[38]  K L Lam,et al.  Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. , 2000, Clinical chemistry.